Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials

Abstract

BACKGROUND: The inflammatory biomarker interleukin-6 (IL-6) is associated with mortality in atrial fibrillation (AF). OBJECTIVE: To investigate if repeated IL-6 measurements improve the prognostication for stroke or systemic embolism, major bleeding, and mortality in anticoagulated patients with AF.

Authors

Aulin J; Hijazi Z; Siegbahn A; Andersson U; Alexander JH; Connolly SJ; Ezekowitz MD; Gersh BJ; Granger CB; Horowitz J

Journal

Journal of Thrombosis and Haemostasis, Vol. 18, No. 9, pp. 2287–2295

Publisher

Elsevier

Publication Date

September 2020

DOI

10.1111/jth.14947

ISSN

1538-7933

Associated Experts

Salim Yusuf

Professor, Faculty of Health Sciences

Visit profile

Labels